Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker by Pan Xie, Pan Xie, Jun-Yan Liu, Han Yan, Zhi-Bin Wang, Zhi-Bin Wang, Shi-Long Jiang, Shi-Long Jiang, Xi Li, Xi Li, Zhao-Qian Liu, Zhao-Qian Liu

Connect to this object online.

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B by Shi-Long Jiang, Shi-Long Jiang, Zhi-Bin Wang, Zhi-Bin Wang, Tao Zhu, Tao Zhu, Ting Jiang, Jiang-Feng Fei, Chong Liu, Chong Liu, Chao Luo, Chao Luo, Yan Cheng, Zhao-Qian Liu, Zhao-Qian Liu

Connect to this object online.

Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells by Mei Wen, Zhen-ke Deng, Shi-long Jiang, Yi-di Guan, Hai-zhou Wu, Xin-luan Wang, Song-shu Xiao, Yi Zhang, Jin-ming Yang, Dong-sheng Cao, Dong-sheng Cao, Yan Cheng, Yan Cheng

Connect to this object online.

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1 by Hai-Zhou Wu, Hai-Zhou Wu, Lan-Ya Li, Lan-Ya Li, Shi-Long Jiang, Yi-Zhi Li, Yi-Zhi Li, Xiao-Mei Shi, Xiao-Mei Shi, Xin-Yuan Sun, Xin-Yuan Sun, Zhuo Li, Yan Cheng, Yan Cheng

Connect to this object online.